Phoenix, AZ 的 多發性骨髓瘤 臨床試驗
16 項針對 多發性骨髓瘤 的研究正在 Phoenix（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Hospital in Arizona, Phoenix
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
招募中4 期
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Mayo Clinic Phoenix, Phoenix
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Mayo Clinic 1, Phoenix
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
招募中3 期
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Cancer Treatment Centers of America-Phoenix, Phoenix
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Arizona, Phoenix
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- Cancer Center at Saint Joseph's, Phoenix
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Phoenix
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Phoenix
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
招募中2 期
- Mayo Clinic - Arizona, Phoenix
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Arizona /ID# 251405, Phoenix
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
招募中3 期
- Cancer Center at Saint Joseph's, Phoenix
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- Banner University Medical Center Tucson, University of Arizona, Phoenix
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
招募中3 期
- GSK Investigational Site, Phoenix
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA42 項研究
- Houston, TX38 項研究
- Durham, NC37 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- Rochester, MN24 項研究
- St. Louis, MO24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Edison, NJ22 項研究
Phoenix 的其他研究
- 乳癌25 項研究
- 大腸直腸癌25 項研究
- 肥胖症22 項研究
- 轉移性癌症20 項研究
- 非小細胞肺癌20 項研究
- 心臟衰竭18 項研究
- 癌症（所有類型）17 項研究
- 前列腺癌17 項研究
- 心血管疾病16 項研究
- 胰臟癌16 項研究
- 過重15 項研究
- 阿茲海默症15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。